Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 5/2012

01-10-2012 | Research Article

Expression of Beclin 1 and LC3 in FIGO stage I–II cervical squamous cell carcinoma and relationship to survival

Authors: Weipei Zhu, Xiaohong Pan, Feng Li, Yongshen Zhang, Xueguan Lu

Published in: Tumor Biology | Issue 5/2012

Login to get access

Abstract

The purpose of this study was to investigate the expression of autophagy-related proteins Beclin 1 and LC3 in cervical normal epithelial cells and squamous cancer cells, and to evaluate the prognostic significance of Beclin 1 and LC3 expression in FIGO stage I–II cervical squamous cell carcinoma. The immunohistochemical expression of Beclin 1 and LC3 were evaluated in 26 formalin-fixed paraffin-embedded cervical normal tissue samples and 50 tumor samples of FIGO stage I–II cervical squamous cell carcinoma, respectively. Correlations with clinicopathologic characteristics were determined by Chi-square test. The prognostic impact of Beclin 1 and LC3 expression in regard to overall survival was determined by Kaplan–Meier method. Cervical normal squamous epithelial cells and cancer cells expressed high Beclin 1 immunoreactivity in 96.2 % (25/26) and 28.0 % (14/50) of patients (p = 0.000), and expressed high LC3 immunoreactivity in 76.9 % (20/26) and 26.0 % (13/50) of patients, respectively (p = 0.000). The expression of both Beclin 1 and LC3 were not associated with age, FIGO stage, pathologic differentiation, and lymph node metastasis. The 3-year overall survival (OS) rates with low and high expressions of Beclin 1 were 72.2 and 100.0 %, respectively (p = 0.034). The 3-year OS rates with low and high expressions of LC3 were 75.7 and 92.3 %, respectively (p = 0.224). These results show that expression level of both Beclin-1 and LC3 were significantly lower in cervical squamous cancer cells than normal squamous epithelial cells. The expression of Beclin 1 and LC3 may have prognostic significance in early stage cervical squamous cell carcinoma.
Literature
1.
Sun Y, Liu JH, Jin L, et al. Over-expression of the Beclin1 gene upregulates chemosensitivity to anti-cancer drugs by enhancing therapy-induced apoptosis in cervix squamous carcinoma CaSki cells. Cancer Lett. 2010;294:204–10.CrossRefPubMed
2.
Komaki R, Brickner TJ, Hanlon AL, et al. Long-term results of treatment of cervical carcinoma in the United States in 1973, 1978 and 1983: patterns of care study (PCS). Int J Radiat Oncol Biol Phys. 1995;31:973–82.CrossRefPubMed
3.
Jermal A, Siegel R, Ward E. Cancer statistics. CA Cancer J Clin. 2009;59:225–49.CrossRef
4.
Lee YY, Choi CH, Kim CJ, et al. The prognostic significance of the SUVmax (maximum standardized uptake value for F-18 fluorodeoxyglucose) of the cervical tumor in PET imaging for early cervical cancer: preliminary results. Gynecol Oncol. 2009;115:65–8.CrossRefPubMed
5.
Kim BS, Kim IJ, Kim SJ, et al. The prognostic value of the metabolic tumor volume in FIGO stage IA to IIB cervical cancer for tumor recurrence: measured by F-18 FDG PET/CT. Nucl Med Mol Imaging. 2011;45:36–42.CrossRefPubMedPubMedCentral
6.
Eisenberg-Lerner A, Kimchi A. The paradox of autophagy and its implication in cancer etiology and therapy. Apoptosis. 2009;14:376–91.CrossRefPubMed
7.
Zois CE, Koukourakis MI. Radiation-induced autophagy in normal and cancer cells: towards novel cytoprotection and radio-sensitization policies? Autophagy. 2009;5:442–50.CrossRefPubMed
8.
Sivridis E, Koukourakis MI, Mendrinos SE, et al. Beclin-1 and LC3A expression in cutaneous malignant melanomas: a biphasic survival pattern for beclin-1. Melanoma Res. 2011;21:188–95.CrossRefPubMed
9.
Karpathiou G, Sivridis E, Koukourakis MI, et al. Light-chain 3A autophagic activity and prognostic significance in non-small cell lung carcinomas. Chest. 2011;140:127–34.CrossRefPubMed
10.
Cheong H, Klionsky DJ. Biochemical methods to monitor autophagy-related processes in yeast. Methods Enzymol. 2008;451:1–26.CrossRefPubMed
11.
Eskelinen EL, Saftig P. Autophagy: a lysosomal degradation pathway with a central role in health and disease. Biochim Biophys Acta. 2009;1793:664–73.CrossRefPubMed
12.
Miracco C, Meng GC, Franchi A, et al. Beclin 1 and LC3 autophagic gene expression in cutaneous melanocytic lesions. Human Pathol. 2010;41:503–12.CrossRef
13.
Klionsky DJ, Abeliovich H, Agostinis P, et al. Guidelines for the use and interpretation of assays for monitoring autophagy in high eukaryotes. Autophagy. 2008;4:151–75.CrossRefPubMedPubMedCentral
14.
Ding ZB, Shi YH, Zhou J, et al. Association of autophagy defect with a malignant phenotype and poor prognosis of hepatocellular carcinoma. Cancer Res. 2008;68:9167–75.CrossRefPubMed
15.
Chen YB, Hou JH, Feng XY, et al. Decreased expression of Beclin 1 correlates with a metastatic phenotypic feature and adverse prognosis of gastric carcinomas. J Surg Oncol. 2012;105:542–7.CrossRefPubMed
16.
Giatromanolaki A, Koukourakis MI, Koutsopoulos A, et al. High Beclin 1 expression defines a poor prognosis in endometrial adenocarcinomas. Gynecol Oncol. 2011;123:147–51.CrossRefPubMed
17.
Sivridis E, Koukourakis MI, Zois CE, et al. LC3A-positive light microscopy detected patterns of autophagy and prognosis in operable breast carcinomas. Am J Pathol. 2010;176:2477–89.CrossRefPubMedPubMedCentral
18.
Chen Y, Lu Y, Lu C, et al. Beclin-1 expression is a predictor of clinical outcome in patients with esophageal squamous cell carcinoma and correlated to hypoxia-inducible factor (HIF)-1α expression. Pathol Oncol Res. 2009;15:487–93.CrossRefPubMedPubMedCentral
19.
Jiang ZF, Shao LJ, Wang WM, et al. Decreased expression of Beclin-1 and LC3 in the human lung cancer. Mol Biol Rep. 2012;39:259–67.CrossRefPubMed
20.
Aoki H, Kondo Y, Aldape K, et al. Monitoring autophagy in glioblastoma with antibody against isoform B of human microtubule-associated protein 1 light chain 3. Autophagy. 2008;4:467–75.CrossRefPubMed
21.
Shen Y, Li DD, Wang LL, et al. Decreased expression of autophagy-related proteins in malignant epithelial ovarian cancer. Autophagy. 2008;16:1067–8.CrossRef
22.
Yoshioka A, Miyata H, Doki Y, et al. LC3, an autophagosome marker, is highly expressed in gastrointestinal cancer. Int J Oncol. 2008;33:461–8.PubMed
23.
Liang XH, Kleeman LK, Jiang HH, et al. Protection against fatal Sindbis virus encephalitis by beclin, a novel Bcl-2-interacting protein. J Virol. 1998;72:8586–96.PubMedPubMedCentral
24.
Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Beclin 1 over- and underexpression in colorectal cancer: distinct patterns relate to prognosis and tumor hypoxia. Br J Cancer. 2010;103:1209–14.CrossRefPubMedPubMedCentral
25.
Fujii S, Mitsunaga S, Yamazaki M, et al. Autophagy is activated in pancreatic cancer cells and correlates with poor patient outcome. Cancer Sci. 2008;99:1813–9.CrossRefPubMed
26.
Cheng HY, Zhang YN, Wu QL, et al. Expression and clinical significance of LC3 in cervical cancer tissues. Chin J Cancer Prev Treat. 2011;18:1247–51.
Metadata
Title
Expression of Beclin 1 and LC3 in FIGO stage I–II cervical squamous cell carcinoma and relationship to survival
Authors
Weipei Zhu
Xiaohong Pan
Feng Li
Yongshen Zhang
Xueguan Lu
Publication date
01-10-2012
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 5/2012
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-012-0421-4

Other articles of this Issue 5/2012

Tumor Biology 5/2012 Go to the issue

Research Article

Inhibition of autocrine IGF-II on effect of human HepG2 cell proliferation and angiogenesis factor expression

Research Article

MCAM is a novel metastasis marker and regulates spreading, apoptosis and invasion of ovarian cancer cells

Research Article

Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo

Research Article

Burden of cancers in the valley of Kashmir: 5 year epidemiological study reveals a different scenario

Research Article

Acquired xanthine dehydrogenase expression shortens survival in patients with resected adenocarcinoma of lung

Research Article

Ferritin as an independent mortality predictor in patients with pancreas cancer. Results of a pilot study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits